- Private Equity Principal and Sector Specialist
- About Us
- My Account
The views expressed are those of the author at the time of writing. Other teams may hold different views and make different investment decisions. The value of your investment may become worth more or less than at the time of original investment. While any third-party data used is considered reliable, its accuracy is not guaranteed. For professional, institutional, or accredited investors only.
The times they are a-changin’. The late-stage private equity market is digesting a public growth multiple collapse that took us from boom to bust in four months. But while valuations may be coming down in the private market as a result, the opportunity-creating trends of technology disrupting all parts of the economy and companies staying private longer remain in place.
The recent inflated valuation environment has finally corrected in a number of areas. For example, consider the software-as-a-service (SaaS) sector of the public market which is now back to the multiples of 2019 (Figure 1).
But how is this public market correction impacting the late-stage private world? We’ve seen prices in some of the most richly valued areas fall significantly, leaving valuations of some prominent private SaaS companies, for instance, looking quite different than they did just a few months ago.
The public market correction is also causing a slowdown in late-stage deal activity. Don’t get us wrong, activity levels remain near all-time highs, but things are tapering off. Looking at first-quarter industry data, venture capital activity as a whole dropped 19% quarter-over-quarter. The number of US$100M+ financings has also fallen each month since reaching a fever pitch in November of last year (Figure 2).
It’s worth noting there is a lag effect in data like this: Companies often wait a month or longer from signing a term sheet to ultimately taking capital in and announcing the raise. So, it is likely that much of the late-stage deal activity announced in the first quarter was actually struck at the end of last year. Our readthrough: The Q2 number could be even more depressed than the Q1 number. In our view, there will undoubtedly still be robust deal activity, just not at the frenzied level of 2021.
Amid today’s changing valuations and cooling deal activity, the new environment is also beginning to shift the behavior of investors. Many may be regretting getting caught up in the high-valuation craze of recent years and may now be pulling back from the market.
But overall, we may actually be heading into a more normalized environment where private prices come down, allowing disciplined investors to identify companies at more favorable valuations with potentially less competition.
Long/short investing in European equities' growing dispersionContinue reading
More from the core: How fundamental extension (140/40) strategies could helpContinue reading
Time for a new playbook on bondsContinue reading
Using market-implied regimes to help build more resilient portfoliosContinue reading
Thematic investing: Long-term thinking for a short-term worldContinue reading
Governance best practices in public markets
For private companies approaching the public markets, we highlight the corporate governance best practices that can help pave strong relationships with public market investors.
Understanding private equity performance
We dive deep on best practices for measuring and benchmarking private equity performance. In addition, we outline the J-curve and the impact of fund lifecycle on returns.
WellSaid: Partnering with portfolio companies
Co-head of private investing Michael Carmen explores how we partner with portfolio companies to help them along the "last mile from the private market to the public market" including on key ESG issues for private companies to consider.
Biotech for the next decade: Private market innovations
We explore our latest research in private biotech innovation across immunomodulatory therapies, precision oncology, antibody drug conjugates, radiopharmaceuticals, genetic medicines, and a range of other novel treatment modalities.
Mid-year Alternative Investment Outlook
This collection provides timely ideas across the spectrum of alternative investments -- including hedge funds, private equity, and private credit.
Cybersecurity for private companies
We highlight today's rising cybersecurity risks, explore how they impact private companies, discuss key regulatory considerations, and share best practices for companies facing these threats.
Opportunity in disguise: Why bad news may be good for alternatives in 2023
Multi-Asset Strategists Nick Samouilhan and Adam Berger explain how alternative investments may help allocators make tailwinds out of macro and market headwinds in the year ahead.
Private credit in 2023: The benefits of a bear market?
We explore conditions in investment-grade private credit and go deeper on how today’s challenging overall market landscape could fuel opportunities for investors.
ESG in private markets: Insights for 2023
We highlight five key areas for private companies to prioritize in 2023 and share the essential steps they can take to keep up with today’s evolving ESG risks and opportunities.